Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating reiterated by Mizuho with a $45.00 price target

Analyst Ratings For Audentes Therapeutics Inc (NASDAQ:BOLD)

Story continues below

Today, Mizuho reiterated its Buy rating on Audentes Therapeutics Inc (NASDAQ:BOLD) with a price target of $45.00.

There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Audentes Therapeutics Inc (NASDAQ:BOLD) is Buy with a consensus target price of $38.8889 per share, a potential 16.82% upside.

Some recent analyst ratings include

  • 8/22/2018-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating reiterated by Mizuho with a $45.00 price target
  • 8/20/2018-Audentes Therapeutics Inc (NASDAQ:BOLD) has coverage initiated with a Neutral rating and $40.00 price target
  • 8/8/2018-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Outperform rating reiterated by Wedbush with a $49.00 price target
  • 8/8/2018-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Hold rating reiterated by Raymond James
  • 8/7/2018-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating reiterated by William Blair
  • 6/25/2018-Audentes Therapeutics Inc (NASDAQ:BOLD) has coverage initiated with a Neutral rating and $35.00 price target

Recent Insider Trading Activity For Audentes Therapeutics Inc (NASDAQ:BOLD)
Audentes Therapeutics Inc (NASDAQ:BOLD) has insider ownership of 6.60% and institutional ownership of 95.94%.

  • On 7/5/2018 Matthew R Patterson, CEO, sold 71,048 with an average share price of $39.55 per share and the total transaction amounting to $2,809,948.40.
  • On 7/3/2018 Matthew R Patterson, CEO, sold 26,901 with an average share price of $40.05 per share and the total transaction amounting to $1,077,385.05.
  • On 7/2/2018 Suyash Prasad, VP, sold 10,000 with an average share price of $38.41 per share and the total transaction amounting to $384,100.00.
  • On 6/25/2018 Louis G Lange, Director, sold 33,000 with an average share price of $40.59 per share and the total transaction amounting to $1,339,470.00.
  • On 6/25/2018 Mary Newman, SVP, sold 8,545 with an average share price of $40.79 per share and the total transaction amounting to $348,550.55.
  • On 6/20/2018 David Nagler, SVP, sold 5,000 with an average share price of $45.29 per share and the total transaction amounting to $226,450.00.
  • On 5/21/2018 Matthew R Patterson, CEO, sold 20,300 with an average share price of $38.15 per share and the total transaction amounting to $774,445.00.

About Audentes Therapeutics Inc (NASDAQ:BOLD)
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Recent Trading Activity for Audentes Therapeutics Inc (NASDAQ:BOLD)
Shares of Audentes Therapeutics Inc closed the previous trading session at 33.29 −0.36 1.07% with 34 shares trading hands.

An ad to help with our costs